Click HERE to register.

Join Matthew T. Ballo, MD, FACR, Hani M. Babiker, MD, and Rupesh Kotecha, MD for this CME-accredited web broadcast that will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the expert panel will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GI and gynecologic tumors.

Activity Description

New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies are revolutionizing the therapeutic management of solid tumors. This new modality of alternating electric field therapy is FDA approved in GBM and MPM and is paving the way for improved outcomes in other solid tumors. As this previously unrecognized antimitotic therapy with a unique mode of delivery continues to be combined with conventional cancer therapies, including surgery, systemic therapy, and radiation therapy, the oncology community will benefit from understanding the practical implications in the multidisciplinary management of cancer.

Target Audience

This activity has been designed to meet the educational needs of radiation oncologists and other clinicians involved in the management of patients with solid tumors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize the mechanistic rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy
• Evaluate the key safety and efficacy evidence on innovative strategies available for the therapeutic management of GBM and MPM
• Review the most recent evidence and ongoing clinical trials on novel therapeutic modalities, including combining TTFields with systemic therapy, radiotherapy, or other modalities, in multiple tumor types such as lung, pancreatic, gastric, liver, and ovarian cancers, across different treatment settings
• Develop strategies to effectively integrate novel technologies into the therapeutic management of patients with cancer, including through appropriate adverse event management and enrollment in clinical trials

Faculty

Chair & Presenter

Matthew T. Ballo, MD, FACR
West Cancer Center & Research Institute
Memphis, Tennessee

Presenters

Hani M. Babiker, MD
University of Arizona Comprehensive Cancer Center
Tucson, Arizona

Rupesh Kotecha, MD
Miami Cancer Institute
Baptist Health South Florida
Miami, Florida

Accreditation

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.